Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
45.00    0.00 (0.00%)
Bid:
44.00
Ask:
46.00
Spread: 2.00 (4.545%)
Market Cap: £86.34m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Q1 2021 Update

15 Apr 2021 07:00

RNS Number : 5130V
Iofina PLC
15 April 2021
 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

 

15 April 2021

 

Iofina plc

("Iofina", the "Company" or the "Group")

(LSE AIM: IOF)

 

Q1 2021 Update

 

Record Q1 Sales, Iodine Market Recovering

 

Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today provides an update to the market regarding its activities during the first quarter of 2021 ("Q1" or the "Period").

 

Highlights

· Strong recovery in the iodine market with sales demand at pre-pandemic levels

· Backlog of deferred orders processed pushed sales for the quarter to record levels

· Global iodine spot prices are increasing and Q2 prices are expected in the $34-$37 range

· Production of 108.2 MT of crystalline iodine (2020: 129.7 MT)

· Decrease compared to Q1 2020 largely due to abnormal extreme weather for two weeks in February

 

During the Period, the Company achieved record sales of iodine and specialty chemicals, as a result of a significant recovery in demand in the iodine market combined with the availability of crystalline iodine inventory that had been stockpiled in H2 2020.

 

The Company produced 108.2 metric tonnes ("MT") of crystalline iodine from its five operating IOsorb® plants in Oklahoma versus 129.7 MT in the same period in 2020. This lower-than-anticipated figure is largely a result of unforeseen storms and extreme cold in the central United States during the month of February, which took production wells offline for approximately two weeks. Additionally, saltwater disposal network system maintenance has resulted in lower water than expected at some plants. With weather related production issues now resolved, Iofina is working with its brine suppliers to maximize supply to our IOsorb® plants. The Company is likely to achieve H1 production of approximately 250MT, below the 285-305 MT forecast.

 

Following a slowdown in H2 2020 given the COVID-19 pandemic and associated effects on the openness and vitality of the U.S. and global economy, the iodine market looks set to recover moving forward with prices steady in Q1 and rising in Q2 2021. Iodine prices are currently at the $34-37/kg level on the spot market, similar to the levels seen in the same period last year, and the Company remains well placed to deliver good margins on its sales.

 

The outlook for iodine prices and demand is likely to be directly related to the rate of the global economic recovery moving out of this COVID-19 period. In particular, iodine demand for X-ray contrast agents, heat stabilizers in automotive applications, and LCD screens, which was significantly reduced last year, is now recovering rapidly. Additionally, Iofina Chemical had larger than expected demand for iodine based biocides in the Period.

The Company is also currently evaluating iodine growth locations and timing, and will prioritise the stability of water supply to our current and future plants. The next potential expansion will most likely be implemented around Q4 2021 or Q1 2022.

 

The Company is planning a webinar for current and potential investors that will likely take place around the time of its full year 2020 results announcement, targeted for May 2021, and the Company will update the market on this in the near future.

Commenting, President and CEO Dr. Tom Becker, stated: "This quarter, Iofina has seen excellent sales for our crystalline iodine and specialty chemical products, a testament to the Company's resilience and ability to capitalise on market recovery as we and the wider economy emerge from the challenging COVID-19 period.

 

"Despite seeing lower production this quarter due to factors outside of our control, we were pleased with the sales figure for the period and are particularly encouraged to see the strong state of the iodine market and its recovery.

 

"Following the Company's debt refinancing in 2020, and our consistent production diversified across plants and product lines, Iofina is on track to prudently continue its growth strategy. I look forward to updating the market further with our FY20 financial results in May."

 

 

Enquiries:

 

Dr. Tom Becker

CEO & President

Iofina plc

Tel: +1 859 356 8000

 

Christopher Raggett/Giles Rolls/Tim Harper (corporate finance)

Tim Redfern (ECM)

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Charles Goodwin/Joe Burgess

Yellow Jersey PR Limited

Tel: +44 (0)7747 788 221

About Iofina:

Iofina plc (AIM: IOF) is a vertically integrated Company that specialises in the production of Iodine and the manufacturing of specialty chemical products. As the second largest producer of iodine in North America, it comprises three USA entities; Iofina Resources, Iofina Chemical and IofinaEX.

 

LEI: 213800QDMFYVRJYYTQ84

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates five producing IOsorb® plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine based products for over 35 years.

 

IofinaEX

Iofina's newest subsidiary, IofinaEX, is fully licensed to process hemp in the state of Kentucky and is currently managing a hemp seed investment in this market.

 

www.iofina.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDZLFFFZLZBBF
Date   Source Headline
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension
17th Jan 20227:00 amRNSQ4 2021 Update
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
29th Dec 20217:00 amRNSBusiness Update
20th Oct 202112:44 pmRNSHolding(s) in Company
15th Oct 20217:00 amRNSQ3 2021 Update
12th Oct 20218:47 amRNSHolding(s) in Company
24th Sep 20217:00 amRNSInterim Results
23rd Sep 20214:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.